Pantoprazole.txt

CLINICAL USE

Gastric acid suppression

DOSE IN NORMAL RENAL FUNCTION

Oral: 20–80 mg in the morningIV: 40–160 mg daily; doses >80 mg in 2 divided doses

PHARMACOKINETICS

Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :383.4

%Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :98

%Excreted unchanged in urine &nbsp &nbsp : 80 (as metabolites)

Volume of distribution (L/kg) &nbsp &nbsp &nbsp :0.15

half-life – normal/ESRD (hrs)&nbsp &nbsp &nbsp :1/2–3

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 &nbsp &nbsp : Dose as in normal renal function

10 to 20 &nbsp &nbsp : Dose as in normal renal function

<10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Not dialysed. Dose as in normal renal function

HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Not dialysed. Dose as in normal renal function

HDF/high flux &nbsp :Unknown dialysability. Dose as in normal renal function

CAV/VVHD &nbsp &nbsp &nbsp:Unknown dialysability. Dose as in normal renal function

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugs

Antifungals: absorption of itraconazole and ketoconazole reduced

ADMINISTRATION

Reconstition

10 mL sodium chloride 0.9%

Route

Oral, IV

Rate of Administration

2–15 minutes

Comments

Use within 12 hours of reconstitution Dilute to 100 mL with sodium chloride 0.9% or glucose 5%.(15.4 mg/mL) 1 mL contains 10 mg anhydrous morphine, 1.2 mg papaverine HCl, and 1.04 mg codeine HCl

Tags: post-by-auto-php